Patented psychobiotic Lactobacillus plantarum PS128™ is now Self-affirmed GRAS
Bened Biomedical Co. Ltd., a global leader of functional probiotics esp. psycho-biotics and REJMIUS, INC. proudly announce the newest Self-affirmed GRAS status of the patented psychobiotic Lactobacillus plantarum PS128™ for the immediate sales and distribution in the United States.
TAIPEI, Taiwan, Dec. 22, 2020 /PRNewswire-PRWeb/ -- Bened Biomedical Co. Ltd., a global leader of functional probiotics esp. psycho-biotics and REJIMUS, INC. proudly announce the newest Self-affirmed GRAS status of the patented psychobiotic Lactobacillus plantarum PS128™ for the immediate sales and distribution in the United States.
"Our commitment and employing a clinical development strategy for novel ingredients such as PS128™ is really leading the way to create evidence-based functional food and supplement products in the marketplace overall," said Frankie Cheng, CEO of Bened Biomedical Co. Ltd. "We want our customers in the United States to know that we are fully dedicated to investing into our products and processes from beginning to end, and ensuring we are a reliable supplier in terms of safety and efficacy as well as all of the compliance requirements from the FDA."
The patented strain of Lactobacillus plantarum PS128™ was developed from extensive research for improvement of mental, neurological, and gastrointestinal health. The Self-affirmed GRAS consensus was attained after a formal and stringent review by an independent expert panel.
"REJIMUS was honored to earn this opportunity to work with Bened Biomedical in bringing such a novel patented ingredient to the U.S.," said Brandon Griffin, CEO of REJIMUS, INC. "In addition to the PS128™ introduction to the U.S. market, the development and implementation of Bened's supply chain and quality systems to better align with that of their U.S. customers' anticipated needs was a tremendous undertaking in these unprecedented times. Many of our clients here in the U.S. have been negatively impacted by their international suppliers due to the pandemic, so guiding Bened Biomedical in the preparation from an operational and compliance standpoint to rapidly attract more customers was paramount."
About Bened Biomedical Co. Ltd.:
Bened Biomedical Co. Ltd., was founded in 2015 in Taipei, Taiwan, as a spin-out company from National Yang-Ming University (NYMU). The company focuses on advanced technologies and products in microbiome-based therapy for mental, neurological, immunological, metabolic, and aging-related disorders. Bened Biomedical develops functional probiotic strains that can alter human microbiome to prevent and treat diseases. For more information, please visit: http://benedbiomed.com/en
About REJIMUS:
REJIMUS is a preeminent regulatory management consulting firm enabling companies in the Food, Dietary Supplement, Animal Feed and Cosmetic industries to develop novel ingredients and finished products, while optimizing their quality programs under all applicable regulations, and managing their regulatory compliance of their operations and supply chain. The company helps in bringing new and novel ingredients and/or finished products to market under compliance, while mitigating overall regulatory and legal risks. For more information on the markets served and regulatory service offerings, please visit: https://www.rejimus.com
Media Contact
Customer Relations, REJIMUS, INC., +1 (949) 229-0072, [email protected]
Brandon Griffin, REJIMUS, INC., 949-485-2112 402, [email protected]
SOURCE Bened Biomedical Co. Ltd.
Share this article